Noveome Biotherapeutics
Phase 1Noveome is advancing its ST266 biologic, a first-of-its-kind, multi-targeted secretome containing hundreds of biologically active proteins and other factors crucial to neuroprotection, the modulation of inflammation, cell recovery and healing. We believe this novel biologic holds significant clinical potential across a range of important underserved conditions in ophthalmology, neurology, dermatology—and beyond.
About
Noveome is advancing its ST266 biologic, a first-of-its-kind, multi-targeted secretome containing hundreds of biologically active proteins and other factors crucial to neuroprotection, the modulation of inflammation, cell recovery and healing. We believe this novel biologic holds significant clinical potential across a range of important underserved conditions in ophthalmology, neurology, dermatology—and beyond.
Funding History
2Total raised: $12M
Company Info
Contact
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile